Posted by Michael Wonder on 17 Dec 2023
FDA approves Arcutis’ Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older
15 December 2023 - Commercial product expected to be available by end of January.
Arcutis Biotherapeutics today announced the US FDA has approved the new drug application for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older.
